BMO Capital analyst Bhavesh Lodaya lowered the firm’s price target on Olin (OLN) to $34 from $44 and keeps a Market Perform rating on the ...

BMO Capital lowered the firm’s price target on FMC (FMC) to $50 from $62 and keeps a Market Perform rating on the shares after its Q4 results ...

BMO Capital Markets has recently initiated Aflac Inc (AFL) stock to Market Perform rating, as announced on January 23, 2025, according to Finviz. Earlier, on October 9, 2024, TD Cowen had initiated ...

Adtalem Global Education (NYSE:ATGE – Get Free Report) had its price objective lifted by equities researchers at BMO Capital Markets from $108.00 to $115.00 in a note issued to investors on ...

Co. Inc. (NYSE:MRK), reducing the pharmaceutical giant's price target from $105.00 to $96.00, while keeping a Market Perform rating on the stock. Analysts at BMO Capital cited a decrease in confidence ...

NIKE (NYSE:NKE – Get Free Report) had its price objective raised by BMO Capital Markets from $92.00 to $95.00 in a research note issued on Monday,Benzinga reports. The firm presently has an ...

BMO Capital Markets adjusted its outlook on Willis Towers Watson (NASDAQ:WTW), reducing the firm's price target from $325.00 to $320.00. Despite the adjustment, the analyst maintained a Market Perform ...

SmartCentres Real Estate Investment Trust ("SmartCentres” or the "Trust”) (TSX:SRU.UN) announced today that it has closed its ...

In terms of valuation, 4D Molecular Therapeutics Inc’s market capitalization stands at $273.67 million. Market cap represents the total value of all outstanding shares and is a key indicator of a ...

The offering is expected to close on or about February 20, 2025 and is subject to the Company receiving all necessary regulatory approvals, including the approval of the TSX Venture Exchange.

February 04, 2025, 08:12 PM ET, BY Robert S., Contributor | Editor: Derek Curry ( Follow on LinkedIn ) ...